Clinical trials: Chorea, Huntington
Huntington Disease
Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor symptoms in patients with Huntington's disease.
- Trial name
- NCT07513844
- Testing
- Low-Intensity Focused Ultrasound Stimulation（LIFU）
- Where
- China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Huntington Disease
Longitudinal Endpoint Assessment of Disease Burden in HD
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
- Trial name
- LEAD-HD (NCT06475898)
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Huntington Study Group
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Huntington Disease
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD).
- Trial name
- NCT03515213
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Escalating Dose Study in Healthy Volunteers With SEN0014196
This is a trial in healthy volunteers to study the safety, tolerability and pharmacokinetics of single and multiple escalating doses of SEN0014196.
- Trial name
- NCT01521832
- Testing
- SEN0014196
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Siena Biotech S.p.A.
Huntington Disease
Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
- Trial name
- PREDICT-HD (NCT00051324)
- Where
- United States
- Volunteers
- 1,700 people
- Sponsor
- Jordan Schultz
Huntington Disease
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, non-randomized, phase I study in which participants with Huntington's Disease will receive three intravenous injections and will be followed…
- Trial name
- SAVE-DH (NCT02728115)
- Testing
- Cellavita HD Lower Dose, Cellavita HD Higher dose
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- Azidus Brasil
Huntington Disease
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease
This is a pilot study to see whether mindfulness-based cognitive therapy, which is a type of psychological therapy, is able to improve the psychological wellbeing of people who have the gene for Huntington's disease.
- Trial name
- NCT02464293
- Testing
- Mindfulness-based cognitive therapy
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Lancaster University
Huntington's Disease
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
- Trial name
- PREQUEL (NCT00920699)
- Testing
- CoQ10
- Where
- 13 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Huntington's Disease
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months).
- Trial name
- NCT00387270
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medivation, Inc.
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Huntington's Disease
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995) to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's…
- Trial name
- Pre-CREST-X (NCT01411150)
- Testing
- Creatine Monohydrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
- Trial name
- NCT07536061
- Testing
- SRP-1005
- Where
- 5 sites in Australia, New Zealand and 2 more
- Volunteers
- 32 people
- Sponsor
- Sarepta Therapeutics, Inc.
Apathy, Huntington's Disease
Apathy Cure Through Bupropion in Huntington's Disease
The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in…
- Trial name
- Action-HD (NCT01914965)
- Testing
- Bupropion
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Huntington Disease
Is Caffeine an Environmental Modifier in Huntington's Disease?
The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.
- Trial name
- CrEAM-HD (NCT03034122)
- Where
- 10 sites in France
- Volunteers
- 77 people
- Sponsor
- University Hospital, Lille
Huntington Disease
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade.
- Trial name
- NEUROHD (NCT00632645)
- Testing
- Olanzapine, Xenazine, Tiapridal
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
N- Homocysteinylated Huntingtin in Huntington's Disease
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: 1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), 2.
- Trial name
- HO-HD (NCT05225051)
- Testing
- skin biopsy
- Volunteers
- 32 people
- Sponsor
- Central Hospital, Nancy, France